Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • pancreatic carcinoma  (1)
Material
Years
Keywords
  • 1
    ISSN: 1569-8041
    Keywords: carboplatin ; fluorouracil ; pancreatic carcinoma ; response ; survival ; toxicity
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Background: Advanced pancreatic cancer is a rapidly fatal disease whosecourse has been little influenced by chemotherapy. Earlier studies have shownsome modest promise for the combination of protracted infusional5-fluorouracil (PIF)and cisplatin. We sought to evaluate a regimen of possibly lesser toxicity,PIF plus weekly carboplatin. Patients and methods: Fifty-four patients with advanced adenocarcinoma ofthe pancreas were treated with a regimen of protracted infusional fluorouracil300 mg/m2/day for 70 days and carboplatin 100mg/m2/weekly on weeks 1 through 10 of a 12-week cycle. Aftera two-week rest, cycles were repeated until progression. Results: Median duration on treatment was 82 days (range 4–490 days).Toxicity was mild. Grade 3–4 toxicities were anemia 11%,leukopenia 6%, thrombocytopenia 2%, nausea/vomiting 7%,diarrhea 9%, mucositis 9%, and renal 2%. Response wasevaluable in 47 patients. There were two complete and seven partial responses(17% overall objective response rate among all patients). Stabledisease for greater than 12 weeks was seen in 19 patients (40%) andprogression in 19 (40%). The median overall survival was 22 weeks(1–99), with 61 weeks median survival in responders (22–99).One-year survival was 13%. Conclusions: Response and survival results with this regimen are at leastequal to the best combination regimens reported, and were obtained with a lowoverall rate of serious toxicity.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...